2,245 Shares in Abbott Laboratories $ABT Acquired by AlphaStar Capital Management LLC

AlphaStar Capital Management LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 2,245 shares of the healthcare product maker’s stock, valued at approximately $305,000.

A number of other institutional investors have also added to or reduced their stakes in ABT. Brighton Jones LLC raised its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares during the period. Rossby Financial LCC bought a new stake in Abbott Laboratories during the 1st quarter worth approximately $35,000. North Capital Inc. bought a new stake in Abbott Laboratories during the 1st quarter worth approximately $41,000. Moody Aldrich Partners LLC bought a new stake in Abbott Laboratories during the 1st quarter worth approximately $354,000. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Abbott Laboratories by 146.8% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,451 shares of the healthcare product maker’s stock worth $325,000 after purchasing an additional 1,458 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on ABT shares. William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Raymond James Financial boosted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Daiwa Capital Markets boosted their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. The Goldman Sachs Group boosted their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Finally, Barclays boosted their price objective on Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a report on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Stock Performance

ABT stock opened at $123.61 on Friday. The firm has a market cap of $214.94 billion, a PE ratio of 15.49, a P/E/G ratio of 2.36 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average of $131.45 and a 200-day moving average of $131.60. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.Abbott Laboratories’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.